logo
Plus   Neg
Share
Email

Rio Tinto To Sell Entire Stake In Rössing Uranium For Up To $106.5 Mln

Anglo- Australian mining giant Rio Tinto (RTNTF,RIO,RIO.L, RTPPF) announced late Sunday that it has entered into a binding agreement to sell its entire 68.62 percent stake in Rössing Uranium Limited to China National Uranium Corporation Limited or CNUC for up to $106.5 million.

Rössing Uranium is the owners of the Rössing mine in Namibia, which is the world's longest-running open pit uranium mine. Operating since 1976, the Rössing business has produced the most uranium of any single mine.

The total consideration comprises an initial cash payment of $6.5 million, payable at completion, and a contingent payment of up to $100 million following completion.

The contingent payment is linked to uranium spot prices and Rössing's net income during the next seven calendar years. In addition, Rio Tinto will receive a cash payment if CNUC sells the Zelda 20 Mineral Deposit during a restricted period following completion. The total consideration is subject to a maximum cap of $106.5 million.

The company said the deal culminates an extensive assessment of strategic options considered in relation to Rössing.

The transaction is subject to certain conditions precedent, including merger approval from the Namibian Competition Commission. Subject to these conditions being met, the transaction is expected to complete in the first half of 2019.

In Australia, Rio Tinto shares were losing 3.50 percent to trade at A$74.09.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT